1. Scrip

Foghorn’s AML/MDS Trial Moved From Partial To Full Clinical Hold

Uveal Melanoma Study Continues

 
• By Mandy Jackson

A Phase I clinical trial of Foghorn’s FHD-286, which was placed on a partial hold in May after one death, is on a full hold now that multiple deaths may be attributed to differentiation syndrome.

Innovation technology with security switch for information security management concept
Foghorn's Phase I trial of FHD-286 in AML/MDS is on a full clinical hold • Source: Shutterstock

Foghorn Therapeutics Inc.’s lead drug candidate FHD-286 has the potential to treat both hematological malignancies and solid tumors, but its future in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) is unclear now that a Phase I dose-escalation trial is on a full clinical hold because multiple patient deaths may be linked to differentiation syndrome.

Cambridge, MA-based Foghorn announced in May that the US Food and Drug Administration put the AML/MDS trial on hold after a patient died from differentiation syndrome

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D